Cesca Therapeutics (KOOL) Issues Earnings Results
Cesca Therapeutics (NASDAQ:KOOL) announced its earnings results on Wednesday. The biotechnology company reported ($0.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.02), Morningstar.com reports. The firm had revenue of $3.11 million during the quarter, compared to the consensus estimate of $2.97 million. Cesca Therapeutics had a negative return on equity of 18.05% and a negative net margin of 322.75%.
Cesca Therapeutics stock traded up $0.01 during trading hours on Thursday, reaching $0.32. The stock had a trading volume of 313,722 shares, compared to its average volume of 431,358. The company has a market capitalization of $5.89 million, a PE ratio of -0.33 and a beta of -0.68. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.97 and a current ratio of 1.93. Cesca Therapeutics has a 52 week low of $0.22 and a 52 week high of $4.14.
KOOL has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of Cesca Therapeutics from a “hold” rating to a “buy” rating and set a $0.25 target price for the company in a report on Wednesday, August 22nd. HC Wainwright set a $2.00 target price on shares of Cesca Therapeutics and gave the stock a “buy” rating in a report on Thursday.
About Cesca Therapeutics
Cesca Therapeutics Inc develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products.
See Also: What is the S&P 500 Index?
Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.